Bg pattern

OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

Omlyclo 150 mg solution for injection in pre-filled syringe

omalizumab

This medicine is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of section 4 will tell you how to report side effects.

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the pack

  1. What is Omlyclo and what is it used for
  2. What you need to know before you use Omlyclo
  3. How to use Omlyclo
  4. Possible side effects
  5. Storage of Omlyclo
  6. Contents of the pack and other information

1. What is Omlyclo and what is it used for

Omlyclo contains the active substance omalizumab. Omalizumab is a human protein, similar to the natural proteins produced by the body. It belongs to a class of medicines called monoclonal antibodies.

Omlyclo is used for the treatment of:

  • allergic asthma
  • chronic rhinosinusitis (inflammation of the nose and sinuses) with nasal polyps
  • chronic spontaneous urticaria (CSU)

Allergic asthma

This medicine is used to prevent asthma from getting worse by controlling symptoms of severe allergic asthma in adults, adolescents and children (from 6 years of age) who are already taking asthma medicines, but whose symptoms are not adequately controlled with medicines such as high-dose inhaled corticosteroids and inhaled beta-agonists.

Chronic rhinosinusitis with nasal polyps

This medicine is used to treat chronic rhinosinusitis with nasal polyps in adults (from 18 years of age) who are taking intranasal corticosteroids (nasal spray with corticosteroids), but whose symptoms are not well controlled with these medicines. Nasal polyps are small growths in the lining of the nose. Omlyclo helps to reduce the size of the polyps and improves symptoms including nasal congestion, loss of sense of smell, mucus in the back of the throat and nasal discharge.

Chronic spontaneous urticaria (CSU)

This medicine is used for the treatment of chronic spontaneous urticaria in adults and adolescents (from 12 years of age) who are already taking antihistamines but whose CSU symptoms are not well controlled by these medicines.

Omlyclo works by blocking a substance called immunoglobulin E (IgE) that is produced by the body. IgE is involved in a type of inflammation that plays a key role in causing allergic asthma, chronic rhinosinusitis with nasal polyps and CSU.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Omlyclo

Do not use Omlyclo

  • if you are allergic to omalizumab or any of the other ingredients of this medicine (listed in section 6).

If you think you may be allergic to any of the ingredients, tell your doctor, as you should not use Omlyclo.

Warnings and precautions

Tell your doctor before using Omlyclo:

  • if you have kidney or liver problems,
  • if you have a condition where your own immune system attacks parts of your own body (autoimmune disease),
  • if you are going to travel to an area where parasitic infections are common, as Omlyclo may reduce your resistance to such infections,
  • if you have had a severe allergic reaction (anaphylaxis) in the past, for example as a result of taking a medicine, an insect sting or food.

Omlyclo does not treat acute asthma symptoms, such as a sudden asthma attack. Therefore, Omlyclo should not be used to treat this type of symptom.

Omlyclo is not intended to prevent or treat other types of allergic conditions, such as sudden allergic reactions, hyperimmunoglobulin E syndrome (inherited immune disorder), aspergillosis (lung disease caused by a fungus), food allergy, eczema or hay fever, as Omlyclo has not been studied in these conditions.

Watch for signs of allergic reactions and other serious side effects

Omlyclo may cause serious side effects. You should watch for signs of these effects while using Omlyclo. Seek medical attention immediately if you notice any signs that indicate a serious allergic reaction or other serious side effects. These signs are mentioned in “Serious side effects” in section 4.

Before you or someone else injects Omlyclo, it is important that you receive training from your doctor on how to recognize the early symptoms of serious allergic reactions and how to act if they occur (see section 3, “How to use Omlyclo”). Most serious allergic reactions occur during the first three doses of Omlyclo.

Children and adolescents

Allergic asthma

Omlyclo is not recommended for children under 6 years of age. Its use in children under 6 years of age has not been studied.

Chronic rhinosinusitis with nasal polyps

Omlyclo is not recommended for children and adolescents under 18 years of age. Its use in patients under 18 years of age has not been studied.

Chronic spontaneous urticaria (CSU)

Omlyclo is not recommended for children under 12 years of age. Its use in children under 12 years of age has not been studied.

Other medicines and Omlyclo

Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.

This is especially important if you are using:

  • medicines to treat a parasitic infection, as Omlyclo may reduce the effect of your medicines,
  • inhaled corticosteroids and other medicines for allergic asthma.

Pregnancy and breastfeeding

If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. Your doctor will discuss with you the benefits and risks of using this medicine during pregnancy.

Tell your doctor immediately if you become pregnant while being treated with Omlyclo.

Omlyclo may pass into breast milk. If you are breastfeeding or plan to breastfeed, ask your doctor for advice before taking this medicine.

Driving and using machines

Omlyclo is unlikely to affect your ability to drive or use machines.

3. How to use Omlyclo

Follow exactly the instructions for administration of this medicine given by your doctor. If you are unsure, ask your doctor, pharmacist or nurse again.

How to use Omlyclo

Omlyclo is used as an injection under the skin (known as a subcutaneous injection).

Omlyclo injection

  • You and your doctor will decide if you will inject Omlyclo yourself. The first three doses will always be injected under the supervision of a healthcare professional (see section 2).
  • It is important that you have received proper training on how to inject the medicine before you do it yourself.
  • The caregiver (e.g. parents) can give the Omlyclo injection after proper training.

To get detailed instructions on how to inject Omlyclo, see “Instructions for use of Omlyclo in pre-filled syringe” at the end of this leaflet.

Training to recognize serious allergic reactions

It is also important that you do not inject Omlyclo yourself until your doctor or nurse has taught you:

  • how to recognize the signs and symptoms of serious allergic reactions,
  • what to do if the symptoms appear.

For more information on the signs and symptoms of serious allergic reactions, see section 4.

How much to use

Allergic asthma and chronic rhinosinusitis with nasal polyps

Your doctor will decide how much Omlyclo you need and how often you need to use it. This depends on your body weight and the results of a blood test done before starting treatment to determine the level of IgE in your blood.

You will need between 1 and 4 injections at the same time. You will need injections every 2 or 4 weeks.

Continue taking your current asthma and/or nasal polyp medicine while you are being treated with Omlyclo. Do not stop any asthma and/or nasal polyp medicine without talking to your doctor.

You may not notice an immediate improvement after starting treatment with Omlyclo. In patients with nasal polyps, the effects have been seen 4 weeks after starting treatment. In patients with asthma, it usually takes between 12 and 16 weeks for the medicine to have its full effect.

Chronic spontaneous urticaria (CSU)

You will need two 150 mg injections at the same time every 4 weeks.

Continue taking your current CSU medicine during treatment with Omlyclo. Do not stop any medicine without talking to your doctor.

Use in children and adolescents

Allergic asthma

Omlyclo can be used in children and adolescents from 6 years of age who are already taking asthma medicine, but whose asthma symptoms are not well controlled by medicines such as high-dose inhaled corticosteroids and inhaled beta-agonists. Your doctor will tell you how much Omlyclo your child needs and how often it should be given. This will depend on the child’s weight and the results of blood tests done before starting treatment to determine the level of IgE in the blood.

Children (from 6 to 11 years of age) are not expected to inject Omlyclo themselves. However, if the doctor thinks it is suitable, the caregiver can give the Omlyclo injection after proper training.

Chronic rhinosinusitis with nasal polyps

Omlyclo should not be used in children and adolescents under 18 years of age.

Chronic spontaneous urticaria (CSU)

Omlyclo can be used in adolescents from 12 years of age who are already taking antihistamines but whose CSU symptoms are not well controlled by these medicines. The dose for adolescents from 12 years of age is the same as for adults.

If you miss a dose of Omlyclo

If you have missed a visit, contact your doctor or hospital as soon as possible to reschedule.

If you have forgotten to inject a dose of Omlyclo, inject it as soon as you remember. Then talk to your doctor to find out when you should have your next dose.

If you stop treatment with Omlyclo

Do not stop treatment with Omlyclo unless your doctor tells you to. Stopping or finishing treatment with Omlyclo may cause your symptoms to come back.

However, if you are being treated for CSU, your doctor may stop treatment with Omlyclo from time to time to assess your symptoms. Follow your doctor’s instructions.

If you have any other questions about the use of this medicine, ask your doctor, pharmacist or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects caused by Omlyclo are usually mild to moderate, but occasionally they can be serious.

Serious side effects:

Seek medical attention immediately if you notice any of the signs of the following side effects:

Rare (may affect up to 1 in 1,000 people)

  • serious allergic reactions (including anaphylaxis). Symptoms may include rash, itching, hives, swelling of the face, lips, tongue, larynx (voice box), trachea or other parts of the body, rapid heartbeat, dizziness and slight feeling of fainting, confusion, shortness of breath, wheezing or difficulty breathing, blue-tinged skin or lips, collapse and loss of consciousness. If you have a history of serious allergic reactions (anaphylaxis) not related to Omlyclo, you may be at greater risk of developing a serious allergic reaction after using Omlyclo.
  • systemic lupus erythematosus (SLE). Symptoms may include muscle pain, pain and swelling of the joints, rash, fever, weight loss and fatigue.

Frequency not known (cannot be estimated from the available data)

  • Churg-Strauss syndrome or hypereosinophilic syndrome. Symptoms may include one or more of the following: swelling, pain or rash around blood vessels or lymph nodes, high level of a specific type of white blood cell (marked eosinophilia), worsening of respiratory problems, nasal congestion, heart problems, pain, numbness, tingling in the arms and legs.
  • low blood platelet count with symptoms such as bleeding or bruising that occurs more easily than normal.
  • serum sickness. Symptoms may include one or more of the following: joint pain with or without swelling or stiffness, rash, fever, swelling of the lymph nodes, muscle pain.

Other side effects include:

Very common (may affect more than 1 in 10 people)

  • fever (in children)

Common (may affect up to 1 in 10 people)

  • injection site reactions including pain, swelling, itching and redness
  • pain in the upper abdomen
  • headache (very common in children)
  • infections of the upper respiratory tract, such as pharyngitis and common cold
  • feeling of pressure or pain in the cheeks and forehead (sinusitis, sinus headache)
  • joint pain (arthralgia)
  • feeling of dizziness

Uncommon (may affect up to 1 in 100 people)

  • feeling of sleepiness or tiredness
  • tingling or numbness of hands or feet
  • fainting, decrease in blood pressure when sitting or standing up (postural hypotension), flushing
  • sore throat, cough, acute respiratory problems
  • feeling of nausea, diarrhea, indigestion
  • itching, hives, rash, increased sensitivity of the skin to the sun
  • weight gain
  • flu-like symptoms
  • swollen arms

Rare (may affect up to 1 in 1,000 people)

  • parasitic infection

Frequency not known (cannot be estimated from the available data)

  • muscle pain and joint inflammation
  • hair loss

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist or nurse, even if it is possible that they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Omlyclo

  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date is the last day of the month stated.
  • Store in the original package to protect from light.
  • Store in a refrigerator (2°C - 8°C). Do not freeze.
  • Do not use any packaging that is damaged or shows signs of deterioration.

6. Container Contents and Additional Information

Composition of Omlyclo

  • The active ingredient is omalizumab. A 1 ml syringe of solution contains 150 mg of omalizumab.
  • The other components are L-arginine hydrochloride, L-histidine monohydrate hydrochloride, L-histidine, polysorbate 20, and water for injectable preparations.

Appearance of Omlyclo and Container Contents

Omlyclo injectable solution is presented as a clear to turbid, colorless to light brownish-yellow solution in a pre-filled syringe.

Omlyclo 150 mg injectable solution is available in packs containing 1 pre-filled syringe and in multiple packs containing 6 (6 x 1) or 10 (10 x 1) pre-filled syringes.

Not all pack sizes may be marketed in your country.

Marketing Authorization Holder

Celltrion Healthcare Hungary Kft.

1062 Budapest

Váci út 1-3. WestEnd Office Building B tower

Hungary

Manufacturer

Nuvisan France SARL

2400, Route des Colles,

06410, Biot,

France

MIDAS Pharma GmbH

Rheinstrasse 49

55218 West Ingelheim Am Rhein

Rhineland-Palatinate

Germany

Kymos S.L.

Ronda de Can Fatjó 7B

Parc Tecnològic del Vallès

08290 Cerdanyola Del Valles

Barcelona

Spain

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

België/Belgique/Belgien

Celltrion Healthcare Belgium BVBA

Tél/Tel: + 32 1 528 7418

[email protected]

Lietuva

Celltrion Healthcare Hungary Kft.

Tel.: +36 1 231 0493

Text in a foreign language with the name of the company Celltrion Healthcare Hungary Kft and a phone number

Luxembourg/Luxemburg

Celltrion Healthcare Belgium BVBA

Tél/Tel: + 32 1 528 7418

[email protected]

Ceská republika

Celltrion Healthcare Hungary Kft.

Tel: +36 1 231 0493

Magyarország

Celltrion Healthcare Hungary Kft.

Tel.: +36 1 231 0493

Danmark

Celltrion Healthcare Denmark ApS

[email protected]

Tlf: +45 3535 2989

Malta

Mint Health Ltd.

Tel: +356 2093 9800

Deutschland

Celltrion Healthcare Deutschland GmbH

Tel: +49 303 464 941 50

[email protected]

Nederland

Celltrion Healthcare Netherlands B.V.

Tel: + 31 20 888 7300

[email protected]

Eesti

Celltrion Healthcare Hungary Kft.

Tel: +36 1 231 0493

[email protected]

Norge

Celltrion Healthcare Norway AS [email protected]

España

CELLTRION FARMACEUTICA (ESPAÑA)

S.L.

Tel: +34 910 498 478

[email protected]

Österreich

Astro-Pharma GmbH

Tel: +43 1 97 99 860

Ελλáδα

ΒΙΑΝΕΞ Α.Ε.

Τηλ: +30 210 8009111 - 120

Polska

Celltrion Healthcare Hungary Kft.

Tel.: +36 1 231 0493

France

Celltrion Healthcare France SAS

Tél.: +33 (0)1 71 25 27 00

Portugal

CELLTRION PORTUGAL, UNIPESSOAL LDA

Tel: +351 21 936 8542

[email protected]

Hrvatska

Oktal Pharma d.o.o.

Tel: +385 1 6595 777

România

Celltrion Healthcare Hungary Kft.

Tel: +36 1 231 0493

Ireland

Celltrion Healthcare Ireland Limited

Tel: +353 1 223 4026

[email protected]

Slovenija

OPH Oktal Pharma d.o.o.

Tel.: +386 1 519 29 22

Ísland

Celltrion Healthcare Hungary Kft.

Sími: +36 1 231 0493

[email protected]

Slovenská republika

Celltrion Healthcare Hungary Kft.

Tel: +36 1 231 0493

Italia

Celltrion Healthcare Italy S.R.L.

Tel: +39 0247927040

[email protected]

Suomi/Finland

Celltrion Healthcare Finland Oy.

Puh/Tel: +358 29 170 7755

[email protected]

Κúπρος

C.A. Papaellinas Ltd

Τηλ: +357 22741741

Sverige

Celltrion Sweden AB [email protected]

Latvija

Celltrion Healthcare Hungary Kft.

Talr.: +36 1 231 0493

Date of Last Revision of this Leaflet:

Other Sources of Information

Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu

INSTRUCTIONS FOR USE OF OMLYCLO PRE-FILLED SYRINGE

Read and follow the instructions for use provided with Omlyclo pre-filled syringe before starting to use it and each time you get a replacement. They may contain new information.

This information does not replace consultation with your healthcare professional about your disease or treatment.

Children (from 6 to less than 12 years of age) should not self-inject Omlyclo pre-filled syringe; however, if the healthcare professional considers it appropriate, a caregiver may administer the injection after receiving proper training.

Omlyclo pre-filled syringe is available in 2 concentrations (see Figure A). These instructions should be followed for the 150 mg/1 ml concentration. The type of pre-filled syringe you receive will depend on the dose prescribed by your healthcare professional (see Figure C: Dosing Table). Check the label on the container and the color of the plunger rod to ensure that the concentration is correct.

Two syringes with colored plunger rods on boxes with doses of 150mg and 75mg respectively

Important Safety Information

  • Keep the pre-filled syringe out of sight and reach of children. The pre-filled syringe contains small parts.
  • Do notopen the sealed container until you are about to use the pre-filled syringe.
  • Do notuse the pre-filled syringe if the container seal or the plastic tray seal is broken, as it may not be safe to use.
  • Do notever leave the pre-filled syringe in a place where others may handle it.
  • Do notshake the pre-filled syringe.
  • Do notremove the cap until just before administering the injection.
  • The pre-filled syringe cannot be reused. Dispose of the used pre-filled syringe in a puncture-resistant container immediately after use (see step 13. Dispose of the pre-filled syringe).

Storage of the Pre-filled Syringe

  • Store the pre-filled syringe in the refrigerator between 2 °C and 8 °C. Keep this medicine closed in its container to protect it from light.
  • Do notfreeze the pre-filled syringe.
  • Remember to remove the pre-filled syringe from the refrigerator and let it reach room temperature (25 °C) for about 30 minutes before preparing it for injection. Keep the pre-filled syringe in the container to protect it from light.
  • The storage time of the pre-filled syringe at room temperature (25 °C) before use should not exceed 7 days.
  • Do notuse the pre-filled syringe after the expiration date shown on the container and on the pre-filled syringe label. If it has expired, return the entire container to the pharmacy.
  • Do notuse the pre-filled syringe if it has been dropped or is visibly damaged.

Parts of the Pre-filled Syringe (see Figure B)

Auto-injector device with labeled parts: plunger, grip wing, window, medicine, needle, and cap before and after use

Online doctors for OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE

Discuss questions about OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80
5.0 (25)
Doctor

Lina Travkina

Family medicine 13 years exp.

Dr. Lina Travkina is a licensed family and preventive medicine doctor based in Italy. She provides online consultations for adults and children, supporting patients across all stages of care – from acute symptom management to long-term health monitoring and prevention.

Areas of medical care include:

  • Respiratory conditions: colds, flu, acute and chronic bronchitis, mild to moderate pneumonia, bronchial asthma.
  • ENT and eye conditions: sinusitis, tonsillitis, pharyngitis, otitis, infectious and allergic conjunctivitis.
  • Digestive issues: gastritis, acid reflux (GERD), IBS, dyspepsia, bloating, constipation, diarrhoea, functional bowel symptoms, intestinal infections.
  • Urological and infectious diseases: acute and recurrent cystitis, bladder and kidney infections, prevention of recurrent UTIs, asymptomatic bacteriuria.
  • Chronic conditions: hypertension, diabetes, hypercholesterolemia, metabolic syndrome, thyroid disorders, excess weight.
  • Neurological and general symptoms: headache, migraine, dizziness, fatigue, sleep disturbances, reduced concentration, anxiety, asthenia.
  • Chronic pain support: back, neck, joint, and muscle pain, tension syndromes, pain associated with osteochondrosis and chronic conditions.

Additional care areas:

  • Preventive consultations and check-up planning.
  • Medical advice and follow-up consultations.
  • Test interpretation and diagnostic guidance.
  • Structured support for undiagnosed complaints.
  • Second opinion on diagnoses and treatment plans.
  • Nutritional and lifestyle support for vitamin deficiencies, anaemia, metabolic issues.
  • Post-operative recovery support and pain management.
  • Preconception counselling and postpartum support.
  • Immunity support and strategies to reduce frequency of infections.

Dr. Travkina combines evidence-based medicine with an attentive, personalised approach. Her consultations focus not only on treatment, but also on prevention, recovery, and long-term wellbeing.

If during the consultation it becomes clear that your case requires in-person assessment or specialised care outside of her scope, the session will be terminated and the payment fully refunded.

Camera Book a video appointment
€70
5.0 (760)
Doctor

Alina Tsurkan

Family medicine 13 years exp.

Dr. Alina Tsurkan is a licensed family medicine physician based in Portugal, offering online consultations for adults and children. She provides professional primary care, with a focus on prevention, accurate diagnosis, and long-term management of acute and chronic conditions.

Dr. Tsurkan supports patients with a wide range of health issues, including:

  • Respiratory infections: cold, flu, bronchitis, pneumonia, and lingering coughs.
  • ENT conditions: sinusitis, tonsillitis, otitis (ear infections), sore throat, allergic rhinitis.
  • Eye conditions: allergic or infectious conjunctivitis, red eyes, irritation.
  • Digestive issues: acid reflux (GERD), gastritis, irritable bowel syndrome (IBS), constipation, bloating, nausea.
  • Urinary and reproductive health: urinary tract infections (UTIs), cystitis, prevention of recurrent infections.
  • Chronic diseases: hypertension, elevated cholesterol, weight management.
  • Neurological complaints: headaches, migraines, sleep disturbances, fatigue, general weakness.
  • Children’s health: fever, infections, digestive issues, follow-ups, vaccination guidance.

She also provides:

  • IMT medical certificates for driving licence exchange in Portugal.
  • Personalised preventive care and wellness consultations.
  • Interpretation of test results and medical reports.
  • Follow-up care and medication review.
  • Support in managing multiple coexisting conditions.
  • Remote prescription management and medical documentation.

Dr. Tsurkan’s approach is evidence-based and holistic. She works closely with each patient to develop an individualised care plan that addresses both symptoms and root causes. Her goal is to empower patients to take control of their health and maintain well-being through lifestyle adjustments, routine check-ups, and early intervention.

Camera Book a video appointment
€55

Frequently Asked Questions

Is a prescription required for OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE?
OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE?
The active ingredient in OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE is omalizumab. This information helps identify medicines with the same composition but different brand names.
Who manufactures OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE?
OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE is manufactured by Celltrion Healthcare Hungary Kft.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to OMLYCLO 150 MG READY-TO-USE INJECTION SOLUTION IN PRE-FILLED SYRINGE?
Other medicines with the same active substance (omalizumab) include OMLYCLO 75 mg Injectable Solution in Pre-filled Syringe, XOLAIR 150 mg POWDER AND SOLVENT FOR INJECTABLE SOLUTION, XOLAIR 150 mg INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media

Preparation for Injection

Table showing doses in mg and number of yellow and blue pre-filled syringes needed for each dose

  1. Gather materials for injection

1.a. Prepare a clean and flat surface, such as a table or counter, in a well-lit area.

1.b. Remove the container(s) containing the necessary pre-filled syringe(s) from the refrigerator to administer the prescribed dose.

Note: Depending on the dose prescribed by your healthcare professional, you may need to prepare one or more pre-filled syringes and inject the contents of all of them. The following table shows how many injections of each concentration are needed for the prescribed dose (see Figure C: Dosing Table).

1.c. Make sure you have the following materials:

  • Container containing the pre-filled syringe

Not included in the container:

  • 1 alcohol swab
  • 1 cotton ball or gauze
  • 1 adhesive bandage
  • Puncture-resistant container

Medicine box with expiration date indicator and magnifying glass pointing to the information CAD: MONTH YEAR at the bottom

  1. Check the expiration date on the container (see Figure D)
  • Do notuse it if the expiration date has passed. If the expiration date has passed, return the entire container to the pharmacy.

Analog clock showing 11:55 next to the indication 30 minutes and a blister pack with a 150mg tablet

  1. Wait 30 minutes

3.a. Leave the unopenedcontainer containing the pre-filled syringe at room temperature (25 °C) for 30 minutes to warm up (see Figure E).

  • Do notheat the pre-filled syringe using heat sources such as hot water or a microwave.
  • If the pre-filled syringe does not reach room temperature, the injection may be uncomfortable and make it difficult to push the plunger rod.

Hand washing under running water with water flowing over the palm and fingers

  1. Wash your hands

4.a. Wash your hands with soap and water and dry them well (see Figure F).

Rear view of human torso showing shaded injection areas on shoulders, hips, and thighs with legend indicating zones for caregiver and self-injection

  1. Choose an injection site (see Figure G)

5.a. You can inject into:

  • The front of the thighs.
  • The lower abdomen, except for the 5 cm around the navel.
  • The outer aspect of the upper arm if you are a caregiver or healthcare professional.
  • Do notadminister the injection into moles, scars, bruises, or areas where the skin is sensitive, red, hard, or cracked.
  • Do notadminister the injection through clothing.
  1. Choose a different injection site for each new injection, at least 2.5 cm away from the area used for the last injection.

Hand holding injection device pressing against the thigh of a seated person

  1. Clean the injection site

6.a. Clean the injection site with an alcohol swab, making a circular motion (see Figure H).

6.b. Let the skin dry before injecting.

  • Do notblow or touch the injection site again before administering the injection.

Auto-injector with enlarged view of internal mechanism showing dose chamber and inscription CAD-MEB YEAR

  1. Inspect the pre-filled syringe

7.a. Open the container.

Hold the body of the pre-filled syringe to lift it out of the tray.

7.b. Inspect the pre-filled syringe and ensure it has the correct medicine (Omlyclo) and dose.

7.c. Look at the pre-filled syringe and ensure it is not cracked or damaged.

7.d. Check the expiration date on the pre-filled syringe label (see Figure I).

  • Do notuse it if the expiration date has passed.

Note: If the expiration date is not visible in the viewing window, you can turn the inner cylinder of the pre-filled syringe until the expiration date is visible.

Syringe needle with beveled tip shown at high magnification with a circle of enlargement detailing the bevel and needle tip

  1. Inspect the medicine

8.a. Look at the medicine and confirm that the liquid is clear to turbid, colorless to light brownish-yellow, and has no particles (see Figure J).

  • Do notuse the pre-filled syringe if the liquid has changed color, is clearly turbid, or contains particles.
  • You may see air bubbles in the liquid. This is normal.

Administration of the Injection

Hand holding auto-injector with arrows indicating movement and circle showing used cartridge in biological waste container

  1. Remove the cap

9.a. Hold the pre-filled syringe by the body with one hand. With the other hand, gently pull the cap to remove it.

  • Do nothold the plunger rod while removing the cap.
  • You may see a drop of liquid on the tip of the needle. This is normal.

9.b. Dispose of the cap immediately in a puncture-resistant container (see step 13. Dispose of the pre-filled syringeand Figure K).

  • Do notput the cap back on the pre-filled syringe.
  • Do notremove the cap until you are ready to administer the injection.
  • Do nottouch the needle. Otherwise, you could prick yourself with the needle.

Hand holding syringe injecting into the skin at a 45-degree angle indicated with a triangle and text OK

  1. Insert the pre-filled syringe into the injection site

10.a. Gently pinch a skin fold at the injection site with one hand.

Note: It is important to pinch the skin to ensure that you inject under the skin (in the fatty area) but not deeper (in the muscle).

10.b. With a quick and dart-like motion, insert the needle completely into the skin fold at an angle of 45 to 90 degrees (see Figure L).

  • Do nottouch the plunger rod while inserting the needle into the skin.

Auto-injector with white button and blue window inserted into arm skin with arrow indicating direction

  1. Administer the injection

11.a. Once the needle is inserted, release the skin fold.

11.b. Slowly push the plunger rod downuntil the entire dose of medicine is injected and the syringe is empty (see Figure M).

  • Do notchange the position of the pre-filled syringe once the injection has started.
  • If the plunger rod is not fully pressed, the needle guard will not extend to cover the needle when it is removed.

Needle inserted into the skin with a blue and gray safety device and a black arrow indicating the direction of insertion

  1. Remove the pre-filled syringe from the injection site

12.a. Once the pre-filled syringe is empty, slowly lift your thumb off the plunger rod until the needle is completely covered by the needle guard (see Figure N).

  • If the needle is not covered, proceed with caution to dispose of the syringe (see step 13. Dispose of the pre-filled syringe).
  • You may have some bleeding (see step 14. Injection site care).
  • In case of contact with the medicine, wash the area that has been in contact with the medicine with water.
  • Do notreuse the pre-filled syringe.
  • Do notrub the injection site.

After the Injection

Hand depositing a used auto-injector into a white container with a biological hazard symbol black circle

  1. Dispose of the pre-filled syringe
  1. To dispose of the prefilled syringe.

13.a. Place the used prefilled syringe in

a puncture-resistant container

immediately after use (see Figure O).

  • Do notthrow (discard) the prefilled

syringe in household trash.

If you do not have a puncture-resistant

container, you may use a household

container that can be closed and is

resistant to punctures. For your safety

and health and that of others, used

needles and syringes should never be

reused. Disposal of unused medication

and all materials that have come into

contact with it will be carried out in

accordance with local regulations.

  • Medicines must notbe thrown

down the drain or into household

waste. Ask your pharmacist how to

dispose of the packaging and medicines

you no longer need. This will help

protect the environment.

  1. Care of the injection site.

14.a. If bleeding occurs, treat the injection site by applying gentle pressure, without rubbing, with

a cotton swab or gauze at the site and apply an adhesive dressing if necessary.